Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Trillium Therapeutics Inc. (TRIL) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/29/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
11/22/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/22/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/19/2021 SC 13D/A Growth Equity Opportunities V, LLC has filed a Schedule 13D for Trillium Therapeutics Inc.
11/17/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/17/2021 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
11/17/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/17/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/17/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/17/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Pfizer Completes Acquisition of Trillium Therapeutics"
11/17/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/16/2021 8-K Other Events  Interactive Data
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
10/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Trillium Therapeutics Receives Final Court Order Approving Arrangement"
10/27/2021 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &...
Docs: "Trillium Securityholders Approve Acquisition by Pfizer CAMBRIDGE, MA, October 26, 2021 / GlobeNewsWire / Trillium Therapeutics Inc. today announced that its securityholders approved a statutory arrangement with PF Argentum ULC a wholly-owned, indirect subsidiary of Pfizer Inc. at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates. The special resolution approving the arrangement was approved by: 99.61% of the votes cast by Trillium shareholders voting as a single class present in person or represented by proxy and entitled to vote at the meeting; and 99.64% of the votes cast by Trillium shareholders ..."
10/20/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/20/2021 8-K Other Events  Interactive Data
10/15/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/15/2021 8-K Other Events  Interactive Data
10/13/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/13/2021 8-K Other Events  Interactive Data
09/27/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/27/2021 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
09/13/2021 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
08/31/2021 SC 13D/A Growth Equity Opportunities V, LLC reports a 6.3% stake in Trillium Therapeutics Inc.
08/23/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/23/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/23/2021 8-K Quarterly results
08/13/2021 8-K Quarterly results
08/13/2021 10-Q Quarterly Report for the period ended June 30, 2021
06/30/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
05/07/2021 10-Q Quarterly Report for the period ended March 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy